Moelis (Moelis) Cash, Cash Equivalents, Marketable Securities

: $186.4 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Moelis's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($160.20 Mil) to Sep. 2023 ($147.45 Mil) but then increased from Sep. 2023 ($147.45 Mil) to Dec. 2023 ($186.42 Mil).

Moelis's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($520.21 Mil) to Dec. 2022 ($206.79 Mil) and declined from Dec. 2022 ($206.79 Mil) to Dec. 2023 ($186.42 Mil).

Moelis Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Moelis's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moelis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

167.81

202.48

520.21

206.79

186.42

Moelis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															206.79	134.62	160.20	147.45	186.42

Moelis Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Moelis (NYSE:MC) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Moelis Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Moelis's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Moelis (Moelis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Capital Markets » Moelis & Co (NYSE:MC) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

17M:Germany 17M:Germany

Address

399 Park Avenue, 4th Floor, New York, NY, USA, 10022

Website

https://www.moelis.com

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.

Executives

Kenneth Moelis	director, 10 percent owner, officer: Chairman and CEO	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Ciafone Katherine Pilcher	officer: Chief Operating Officer	399 PARK AVE, NEW YORK NY 10022
Kenneth Shropshire	director	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10011
Elizabeth Crain	officer: Chief Operating Officer	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Navid Mahmoodzadegan	director, officer: Managing Director	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Osamu R. Watanabe	officer: General Counsel and Secretary	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Jeffrey Raich	director, officer: Managing Director	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Christopher Callesano	officer: SVP & Principal Acct Officer	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Laila Worrell	director	399 PARK AVENUE, NEW YORK NY 10022
Joseph Simon	officer: Chief Financial Officer	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
Yolonda C Richardson	director	399 PARK AVENUE, NEW YORK NY 10022
Leaman J Richard Iii	director, officer: Managing Partner	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022
John A Allison	director	PO BOX 1250, WINSTON SALEM NC 27102-1250
Yvonne Greenstreet	director	PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Eric Cantor	director	C/O MOELIS & COMPANY, 399 PARK AVENUE, 5TH FLOOR, NEW YORK NY 10022